Trials / Completed
CompletedNCT00617123
Trial to Assess the Ocular Safety of Vorapaxar (SCH 530348) in Participants With Atherosclerosis (Study P05183)
A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Ocular Safety of SCH 530348 in Subjects Participating in the Schering-Plough P04737 Study (TRA^SM-Secondary Prevention Ocular Safety Study)
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 258 (actual)
- Sponsor
- Merck Sharp & Dohme LLC · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study is designed to evaluate the long-term ocular safety of SCH 530348 (vorapaxar) in participants with established atherosclerotic disease who are enrolled into the TRA 2°P - TIMI 50 Study (P04737) (NCT00526474).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Vorapaxar 2.5 mg | Vorapaxar 2.5 mg oral tablet |
| DRUG | Placebo | matching placebo oral tablet |
Timeline
- Start date
- 2008-07-01
- Primary completion
- 2010-10-01
- Completion
- 2010-10-01
- First posted
- 2008-02-15
- Last updated
- 2018-09-21
- Results posted
- 2014-07-14
Source: ClinicalTrials.gov record NCT00617123. Inclusion in this directory is not an endorsement.